Best of ASCO - 2014 Annual Meeting

 

Welcome

Attend this session at the
2019 ASCO Annual Meeting!


Session: Sarcoma

Type: Oral Abstract Session

Time: Monday June 3, 8:00 AM to 11:00 AM

Location: E450

Activity and safety of cabozantinib in patients with gastrointestinal stromal tumor after failure of imatinib and sunitinib: EORTC phase II trial 1317 CaboGIST.

Sub-category:
Gastrointestinal Stromal Tumors (GIST)

Category:
Sarcoma

Meeting:
2019 ASCO Annual Meeting

Abstract No:
11006

Citation:
J Clin Oncol 37, 2019 (suppl; abstr 11006)

Author(s): Patrick Schoffski, Olivier Mir, Bernd Kasper, Zsuzsanna Papai, Jean-Yves Blay, Antoine Italiano, Charlotte Benson, Katerina Kopeckova, Nasim Ali, Palma Dileo, Axel Le Cesne, Franka Menge, Sophie Cousin, Celine Charon-Barra, Agnieszka Wozniak, Sandrine Marreaud, Saskia Litiere, Axelle Nzokirantevye, Hans Gelderblom; Laboratory of Experimental Oncology, Department of Oncology, KU Leuven, and Department of General Medical Oncology, University Hospitals Leuven, Leuven Cancer Institute, Leuven, Belgium; Gustave Roussy, Villejuif, France; Universitaersmedizin Mannheim ITZ, Heidelberg, Germany; Allami Egeszsegugyi Kozpont (State Health Center), Budapest, Hungary; Centre Léon Bérard, Lyon, France; Institut Bergonié, Bordeaux, France; The Royal Marsden Hospital, London, United Kingdom; Department of Oncology, University Hospital Motol, Prague, Czech Republic; Clatterbrige Cancer Centre, Wirral, United Kingdom; University College London Hospitals NHS Foundation Trust, London, United Kingdom; Institut Gustave Roussy (IGR), Villejuif, France; University Medical Center Mannheim, Department of Surgery, Mannheim, Germany; Centre Georges François Leclerc, Dijon, France; Leuven Cancer Institute, KU Leuven, Leuven, Belgium; European Organisation for Research and Treatment of Cancer (EORTC), Brussels, Belgium; European Organisation for Research and Treatment of Cancer, Brussels, Belgium; European Organization for Research and Treatment of Cancer, Brussels, Belgium; Leiden University Medical Center, Department of Medical Oncology, Leiden, Netherlands

Abstract Disclosures

Abstract:

Background: Gastrointestinal stromal tumor (GIST) is the most common mesenchymal malignancy of the gastrointestinal tract. Advanced GIST is treated with tyrosine kinase inhibitors (TKIs). Most patients (pts) develop resistance over time. We reported in 2013 (Van Looy CTOS) that cabozantinib (cabo), a TKI targeting KIT/MET/AXL/VEGFR, showed activity in GIST xenograft models through inhibition of tumor growth, proliferation and angiogenesis, both in imatinib-sensitive and -resistant tumors (Gebreyohannes Mol Cancer Ther 2016;15:2845-28). Cohen (Cancer Res 2015;75:2061-70) found that cabo can overcome compensatory MET signaling in GIST in vitro. EORTC 1317 assessed the safety and activity of cabo in pts who had progressed on imatinib and sunitinib. Methods: In this multi-center, open label, single arm Phase 2 study eligible metastatic GIST pts received 60 mg (freebase weight) cabo p.o./d. Primary endpoint was progression-free survival rate at wk 12, assessed by local investigator per RECIST 1.1. If at least 21 of 41 eligible and evaluable pts were progression-free at wk 12, the activity of cabo was sufficient to warrant further exploration (A’Hern one-stage design). Results: A total of 50 consenting pts were eligible and started treatment between 02/2017 and 08/2018, with 16 (32%) still continuing cabo at the database cut-off in 01/2019. The number of 3 wk treatment cycles ranges from 2-28+. Among the first 41 eligible and evaluable pts, 24 were progression-free at wk 12, satisfying the study decision rule. Among all 50 pts, 30 were progression-free at wk 12 (60%, 95% confidence interval (CI) 45-74%). A total of 7 pts achieved a confirmed partial response (PR) (14%, 95%CI 6-27%) and 33 had stable disease (SD) (66%, 95%CI 51-79%). Progression as best response was seen in 9 pts (18%, 95%CI 9-31%), one was not evaluable. Disease control (PR+SD) was achieved in 40 pts (80%, 95%CI 66-90%). Median progression-free survival was 6.0 mo (95%CI 3.6-7.7). The most common cabo-related grade ≥3 adverse events were diarrhea (74%), hand-foot syndrome (58%), fatigue (46%), hypertension (46%), weight loss (38%) and oral mucositis (28%), with 33 (66%) pts requiring dose reductions, 25 (50%) treatment interruptions and no cabo-related deaths. Conclusions: EORTC 1317 met its primary endpoint, with 24/41 pts (58.5%) being progression-free at wk 12. Results of this trial confirm preclinical data and warrant further exploration of cabo in GIST. Clinical trial information: NCT02216578

 
Other Abstracts in this Sub-Category:

 

1. A randomized phase II study of nivolumab monotherapy versus nivolumab combined with ipilimumab in advanced gastrointestinal stromal tumor (GIST).

Meeting: 2019 ASCO Annual Meeting Abstract No: 11017 First Author: Arun S. Singh
Category: Sarcoma - Gastrointestinal Stromal Tumors (GIST)

 

2. Clinical activity of avapritinib in ≥ fourth-line (4L+) and PDGFRA Exon 18 gastrointestinal stromal tumors (GIST).

Meeting: 2019 ASCO Annual Meeting Abstract No: 11022 First Author: Michael C. Heinrich
Category: Sarcoma - Gastrointestinal Stromal Tumors (GIST)

 

3. ALT-GIST: Randomized phase II trial of imatinib alternating with regorafenib versus imatinib alone for the first-line treatment of metastatic gastrointestinal stromal tumor (GIST).

Meeting: 2019 ASCO Annual Meeting Abstract No: 11023 First Author: Desmond Yip
Category: Sarcoma - Gastrointestinal Stromal Tumors (GIST)

 

More...